Intervacc AB Market Cap ($31.54 Million)
Market Cap & Net Worth: Intervacc AB (IVACC)
Intervacc AB market cap. Intervacc AB (ST:IVACC) has a market capitalization of $31.54 Million (Skr293.10 Million) as of November 5, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #23387 globally and #441 in its home market, demonstrating a 11.11% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Intervacc AB's stock price Skr0.86 by its total outstanding shares 340813188 (340.81 Million). Also see IVACC cash flow metrics for how efficiently the company converts equity into cash flow.
Intervacc AB Market Cap History (2017–2026)
Intervacc AB market cap history from 2017 to 2026. Data shows change from $278.74 Million to $31.54 Million (-20.45% CAGR). Check Intervacc AB stock quote for real-time trading data and today's change.
Index Memberships
Intervacc AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.32 Billion | 0.21% | #78 of 281 |
Weight: Intervacc AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Intervacc AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Intervacc AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Intervacc AB (IVACC) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
3.64x
Intervacc AB's market cap is 3.64 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $278.74 Million | $48.00 Million | -$12.77 Million | 5.81x | N/A |
| 2018 | $245.74 Million | $35.60 Million | -$27.49 Million | 6.90x | N/A |
| 2019 | $662.02 Million | $12.14 Million | -$27.89 Million | 54.54x | N/A |
| 2020 | $1.94 Billion | $4.78 Million | -$25.60 Million | 405.13x | N/A |
| 2021 | $1.95 Billion | $5.24 Million | -$29.38 Million | 372.30x | N/A |
| 2022 | $953.60 Million | $9.68 Million | -$64.16 Million | 98.47x | N/A |
| 2023 | $232.17 Million | $8.02 Million | -$102.85 Million | 28.97x | N/A |
| 2024 | $42.91 Million | $11.79 Million | -$75.52 Million | 3.64x | N/A |
Competitor Companies of IVACC by Market Capitalization
Companies near Intervacc AB in the global market cap rankings as of November 5, 2026. Also see Intervacc AB balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Intervacc AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Intervacc AB (2017–2026)
Market capitalization of Intervacc AB from 2017 to today. Between 2017 and today, Intervacc AB's market cap moved from $278.74 Million to $ 31.54 Million, with a yearly change of -20.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr31.54 Million | -6.93% |
| 2025 | Skr33.89 Million | -21.03% |
| 2024 | Skr42.91 Million | -81.52% |
| 2023 | Skr232.17 Million | -75.65% |
| 2022 | Skr953.60 Million | -51.13% |
| 2021 | Skr1.95 Billion | +0.76% |
| 2020 | Skr1.94 Billion | +192.52% |
| 2019 | Skr662.02 Million | +169.40% |
| 2018 | Skr245.74 Million | -11.84% |
| 2017 | Skr278.74 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Intervacc AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $31.54 Million USD |
| MoneyControl | $31.54 Million USD |
| MarketWatch | $31.54 Million USD |
| marketcap.company | $31.54 Million USD |
| Reuters | $31.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Intervacc AB
Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company's product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages… Read more